MabCure starts trial of ovarian cancer diagnostic
This article was originally published in Clinica
MabCure has started a trial to evaluate its monoclonal antibodies (MAbs) in diagnosing ovarian cancer. The study, which is being carried out at the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand, will enrol patients suspected of having the disease. A spokesperson for MabCure (New York and Hasselt, Belgium) declined to give further details, but did say that the company hopes the test will eventually be used for diagnosing ovarian cancer earlier than is currently possible. The disease is often detected at a late stage, leading to a low survival rate, but five-year survival rates could be increased to over 90% if it was identified earlier. MabCure’s is also developing MAbs for other cancers, including prostate and colorectal.